Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 13/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR1B | P28222 | 5/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812173 | 1.00 | HTR1D (0.55) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6808402 | 0.88 | HTR1D (0.53) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL5088740 | 0.88 | HTR1D (0.53) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6810878 | 0.88 | MAPT (0.46) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6811669 | 0.85 | HTR1D (0.42) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6811442 | 0.85 | HTR1D (0.42) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL8549578 | 0.83 | HTR1D (0.62) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6812036 | 0.82 | HTR1D (0.47) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL8554144 | 0.82 | HTR1D (0.61) | HTR1DDRD2HTR2AHTR1BHTR1A | |
| SCHEMBL6995396 | 0.81 | HTR1D (0.51) | HTR1DDRD2HTR2AHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR1D 124/4885DRD2 1606/4885HTR2A 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.